

FISCH, HARRY
DOCTOR
 C1720 - HARRY FISCH, M.D.
 944 PARK AVENUE,
 NEW YORK, NY 10028
 Acct #: (C1720) **S1**
 P: (212)879-0800

EPSTEIN, JEFFREY
P DOB: [REDACTED] **Age:** 63 **Y** **Sex:** M
A U/FL: **Bed:**
T Rm:
I Patient ID:
E Address: 9 EAST 71ST STREET,
N NEW YORK, NY 10021
T P: (212)772-9416

SAMPLE
Specimen ID: 102449709
Date Of Report: 01/28/2016 02:32
Date Collected: 01/27/2016 12:37
Date Received: 01/27/2016 23:01
 North America Eastern Time

Notes: NON FASTING

CLINICAL REPORT

Clinical Abnormalities Summary: (May not contain all abnormal results; narrative results may not have abnormal flags. Please review entire report.)

Triglycerides	459 HI	HDL CHOL., DIRECT	24 LO
INTR.NORM.RATIO(INR)	0.97 LO		
PROLACTIN, SERUM	3.0 LO	Hemoglobin A1C	6.0 HI

-----* CHEMISTRY *-----						
Test	Result	Abnormal	Reference	Units	Previous Result	Date
Total Protein	6.7		5.9-8.4	g/dL	7.1	10/27/2015
Albumin	4.2		3.5-5.2	g/dL	4.6	10/27/2015
Globulin	2.5		1.7-3.7	g/dL	2.5	10/27/2015
A/G Ratio	1.7		1.1-2.9		1.8	10/27/2015
Glucose	99		70-99	mg/dL	95	10/27/2015
Sodium	141		135-147	mmol/L	135	10/27/2015
NOTE: New reference range for Sodium effective 11/16/15.						
Potassium	4.2		3.5-5.5	mmol/L	4.2	10/27/2015
NOTE: New reference range for Potassium effective 11/16/15.						
Chloride	102		96-108	mmol/L	96	10/27/2015
CO2	26		22-29	mmol/L	26	10/27/2015
BUN	22		8-23	mg/dL	21	10/27/2015
Creatinine	1.11		0.80-1.30	mg/dL	1.03	10/27/2015
e-GFR	70		>or=60	mL/min	77	10/27/2015
e-GFR, African American	81		>or=60	mL/min	89	10/27/2015
BUN/Creat Ratio	19.8		10.0-28.0		20.4	10/27/2015
Calcium	9.8		8.6-10.4	mg/dL	9.7	10/27/2015
Uric Acid	7.5		3.4-8.5	mg/dL	6.2	10/27/2015
Iron	75		45-160	ug/dL	57	10/27/2015
Bilirubin, Total	0.5		<1.2	mg/dL	0.5	10/27/2015
LD	171		135-225	U/L	177	10/27/2015
Alk Phos	43		40-156	U/L	62	10/27/2015
AST	29		<40	U/L	23	10/27/2015
PHOSPHORUS	3.4		2.7-4.5	mg/dL	3.3	10/27/2015
ALT	29		<41	U/L	25	10/27/2015
GGTP	18		10-71	U/L	15	10/27/2015
-* CARDIOVASCULAR/LIPIDS *--						
Cholesterol	143		<200	mg/dL	210 HI	10/27/2015

D O C T O R
FISCH, HARRY
C1720 - HARRY FISCH, M.D.
944 PARK AVENUE,
NEW YORK, NY 10028
Acct #: (C1720) S1
P: (212)879-0800

P A T I E N T
EPSTEIN, JEFFREY
DOB: [REDACTED] Age: 63 Y Sex: M
U/FL: Bed:
Rm:
Patient ID:
Address: 9 EAST 71ST STREET,
NEW YORK, NY 10021
P: (212)772-9416

S A M P L E
Specimen ID: 102449709
Date Of Report: 01/28/2016 02:32
Date Collected: 01/27/2016 12:37
Date Received: 01/27/2016 23:01

North America Eastern Time

CLINICAL REPORT

Test	Result	Abnormal	Reference	Units	Previous Result	Date
Triglycerides		459 HI	<150	mg/dL	348 HI	10/27/2015
HDL CHOL., DIRECT		24 LO	>40	mg/dL	29 LO	10/27/2015
HDL as % of Cholesterol	17		>14	%	14 *	10/27/2015
Evaluation: AVERAGE RISK						
Chol/HDL Ratio	6.0		<7.4		7.2	10/27/2015
Evaluation: AVERAGE RISK						
LDL/HDL Ratio	Can't Calc		<3.56		3.83 HI	10/27/2015
LDL Cholesterol	Can't Calc		<100	mg/dL	111 HI	10/27/2015
NOTE: Unable to calculate LDL due to a Triglyceride level of greater than 400 mg/dL.						
VLDL, CALCULATED	Can't Calc		7-32	mg/dL	70 HI	10/27/2015
Can't Calc: One or more components was outside the measurable range. We are unable to calculate.						
-----* HEMATOLOGY *-----						
WBC	7.12		3.40-11.80	x10(3)/uL	6.33	10/27/2015
RBC	4.96		4.20-5.90	x10(6)/uL	5.01	10/27/2015
HGB	14.3		12.3-17.0	gm/dL	14.6	10/27/2015
HCT	41.3		39.3-52.5	%	41.9	10/27/2015
MCV	83.3		80.0-100.0	fL	83.6	10/27/2015
MCH	28.8		25.0-34.1	pg	29.1	10/27/2015
MCHC	34.6		29.0-35.0	gm/dL	34.8	10/27/2015
RDW	13.9		10.9-16.9	%	14.4	10/27/2015
POLYS	49.2		36.0-78.0	%	51.1	10/27/2015
LYMPHS	36.2		12.0-48.0	%	37.1	10/27/2015
MONOS	7.6		0.0-13.0	%	5.8	10/27/2015
EOS	6.5		0.0-8.0	%	5.4	10/27/2015
BASOS	0.4		0.0-2.0	%	0.6	10/27/2015
IMMATURE GRANULOCYTES	0.1		0.0-1.6	%	0.0	10/27/2015
Platelet Count	222		144-400	x10(3)/uL	257	10/27/2015
MPV	9.5		8.2-11.9	fL	9.0	10/27/2015
PT	10.1		9.1-11.9	sec	10.0 LO	10/27/2015
NOTE: New reference range for Prottime effective 11/10/15.						
INTR.NORM.RATIO(INR)		0.97 LO	2.00-3.00		0.92 LO	10/27/2015
CLINICAL INDICATIONS FOR INR USE						

FISCH, HARRY
D
O
C
T
O
R
R
 C1720 - HARRY FISCH, M.D.
 944 PARK AVENUE,
 NEW YORK, NY 10028
 Acct #: (C1720) **S1**
 P: (212)879-0800

EPSTEIN, JEFFREY
P DOB: ██████████ Age: 63 Y Sex: M
A U/FL: Bed:
T Rm:
I Patient ID:
E Address: 9 EAST 71ST STREET,
N NEW YORK, NY 10021
T
 P: (212)772-9416

S
A
M
P
L
E
 Specimen ID: 102449709
 Date Of Report: 01/28/2016 02:32
 Date Collected: 01/27/2016 12:37
 Date Received: 01/27/2016 23:01
 North America Eastern Time

CLINICAL REPORT

Test	Result	Abnormal	Reference	Units	Previous Result	Date
Reference Range						
Prophylaxis or treatment of venous thrombosis, systemic embolization, and pulmonary embolus			2.00-3.00			
High-risk patients with mechanical heart valves			2.50-3.50			
Normal Non-Medicated patients			0.87-1.15 (effective 11-10-15)			
NOTE: INR values below 2.00 for patients on warfarin therapy would be considered sub-therapeutic for the above conditions.						
PTT	26.5		23.6-31.6	sec	27.6	10/27/2015

NOTE: The modified activated Partial Thromboplastin Time (APTT) is a screening procedure for assessment of secondary coagulation, e.g. whether sufficient fibrinogen and plasma factors are present in amounts for adequate hemostasis. The extension of the stability to 24 hours for the APTT is only valid in its use as an initial screening assay of non-hospitalized patient population. Assessment of factor assays, unfractionated heparin monitoring, mixing studies, and evaluation for antiphospholipid-associated APTT abnormalities ("Lupus anticoagulant") requires strict frozen plasma.

-----* MISCELLANEOUS *-----

TSH	1.790		0.178-4.530	uIU/mL	2.060	10/27/2015
THYROXINE (T4)	6.3		4.9-12.9	ug/dL	7.5	10/27/2015
T3 UPTAKE (T3U)	29.3		24.3-39.0	%	29.1	10/27/2015
THYROXINE, FREE (FT4)	0.93		0.80-1.73	ng/dL	1.06	10/27/2015
FREE T4 INDEX	1.8		1.5-3.8		2.2	10/27/2015
T3 (THYRONINE), TOTAL	127		72-180	ng/dL	129	10/27/2015
PSA Total	0.70		<4.00	ng/mL	0.87	10/27/2015

NOTE: The PSA assay should not be the only test used for diagnostic purposes. Additional evaluation using DRE, ultrasound, TUR or similar procedures may be used for this purpose. Predictions of disease recurrence should not be based solely upon values obtained from serial PSA values obtained on the patient.

NOTE: Values obtained with different assay methods or kits cannot be used interchangeably.

NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics)

PSA, FREE	0.33		Not Estab.	ng/mL	0.31	10/27/2015
-----------	------	--	------------	-------	------	------------

FISCH, HARRY
DOCTOR
 C1720 - HARRY FISCH, M.D.
 944 PARK AVENUE,
 NEW YORK, NY 10028
 Acct #: (C1720) **S1**
 P: (212)879-0800

EPSTEIN, JEFFREY
 P DOB: [REDACTED] Age: 63 Y Sex: M
 A U/FL: Bed:
 T Rm:
 I Patient ID:
 E Address: 9 EAST 71ST STREET,
 N NEW YORK, NY 10021
 T P: (212)772-9416

SAMPLE
 Specimen ID: 102449709
 Date Of Report: 01/28/2016 02:32
 Date Collected: 01/27/2016 12:37
 Date Received: 01/27/2016 23:01
 North America Eastern Time

CLINICAL REPORT

Test	Result	Abnormal	Reference	Units	Previous Result	Date
NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. Values obtained with different assay methods or kits cannot be used interchangeably.						
ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics).						
% FREE PSA	47		See Below	%	36	10/27/2015

FREE PSA RISK ASSESSMENT

The probability of prostate cancer for men with non-suspicious DRE results, by age group, using PSA values between 4.000 and 10.000 ng/mL and percent FREE PSA values is summarized in the table below:

PROBABILITY OF CANCER*

%free PSA	(50-59 yrs)	(60-69 yrs)	(>or=70 yrs)
<or=10	49.2%	57.5%	64.5%
11-18	26.9%	33.9%	40.8%
19-25	18.3%	23.9%	29.7%
>25	9.1%	12.2%	15.8%

*probability of finding prostate cancer by needle biopsy

NOTE: Calculation of percent FREE PSA may not be possible when the value for TOTAL PSA is in the low normal range. These guidelines are for assays performed using the Roche E170 immunoassay system.(02/2012;v5)

TESTOSTERONE, TOT.,S.	296.0		193.0-740.0	ng/dL	112.3 LO	10/27/2015
TESTOSTERONE, BIOAVAIL.	183.8		72.0-460.0	ng/dL	74.6	10/27/2015
SEX HORM.BIND.GLOB.	18		10-57	nmol/L	14	10/27/2015
FREE TESTOSTERONE	80.18		30.00-150.00	pg/mL	29.82 LO	10/27/2015
LH	6.8		1.7-8.6	mIU/mL	3.7	10/27/2015
FSH	6.8		1.5-12.4	mIU/mL	4.0	10/27/2015
PROLACTIN, SERUM		3.0 LO	4.0-15.2	ng/mL	3.4 LO	10/27/2015
ESTRADIOL	48.93		7.02-49.06	pg/mL	16.00	10/27/2015
FIBRINOGEN	276		176-441	mg/dL	362	10/27/2015
Hemoglobin A1c		6.0 HI	<5.7	%	5.9 HI	10/27/2015

HEMOGLOBIN A1c AND eAG REFERENCE RANGES

A1c(%)	DIABETES CATEGORY*
<5.7	Normal (non-diabetic)
5.7-6.4	Increased risk of diabetes
=>6.5	Consistent with diabetes

A1c(%)	eAG(ESTIMATED AVERAGE PLASMA GLUCOSE)(mg/dL)
...

FISCH, HARRY
DOCTOR
 C1720 - HARRY FISCH, M.D.
 944 PARK AVENUE,
 NEW YORK, NY 10028
 Acct #: (C1720) **S1**
 P: (212)879-0800

EPSTEIN, JEFFREY
P DOB: [REDACTED] **Age:** 63 Y **Sex:** M
A U/FL: **Bed:**
T Rm:
I Patient ID:
E Address: 9 EAST 71ST STREET,
N NEW YORK, NY 10021
T
 P: (212)772-9416

SAMPLE
Specimen ID: 102449709
Date Of Report: 01/28/2016 02:32
Date Collected: 01/27/2016 12:37
Date Received: 01/27/2016 23:01
North America Eastern Time

CLINICAL REPORT

Test	Result	Abnormal	Reference	Units	Previous Result	Date
	6	126				
	7	154				
	8	183				
	9	212				
	10	240				
	11	269				
	12	298				
*recommended ranges-American Diabetes Association(2010)						
NOTE: Hemolysis, rare hemoglobin variants and thalassemia major may affect glyceimic results.						
DIHYDROTESTOSTERONE	TO FOLLOW		SEE REPORT		153.0	10/27/2015